 we report on our fourth quarter and year-end financial results and provide a snap shot of our financial position and review the upcoming investor conference calendar. 2016 and the fourth quarter especially were marked by notable achievements and advancements for Abeona and our goals for expanding and building ourselves as a rare disease leading gene therapy company. to go over some of the milestones that we achieved, particularly in the clinical domain, we will talk a little bit about our lead program ABO 102, which is a treatment, gene therapy treatment for the patients with Sanfilippo syndrome type a. we have met many of our goals for advancing this lead gene therapy program, it is the only one in the clinic in 2016 and currently in 2017 that is enrolling patients for patients with patients with Sanfilippo syndrome. we reported on positive clinical data in our lead program for Sanfilippo syndrome type a, as well as our programs for Epidermolysis Bullosa, and we achieved multiple regulatory designations in multiple programs. we are already building on the granted rare disease Pediatric Designation and the Orphan Drug Designation in the United States. our second lead gene therapy program is in the form of autologous keratinocyte corrective gene therapy for a horrifying disease called epider